Impacts of Remnant Cholesterol and Residual Inflammation on Clinical Outcomes After Ischemic Stroke Authors: Yunhao Chen, Yanyu Zhu, Mingzhe Du, Yanbo Peng, Tan Xu, Yonghong Zhang, Hui Li, Chongke Zhong Published: 2026 ABSTRACT BackgroundAlthough remnant cholesterol (RC) and residual inflammation are established risk factors for stroke, their joint prognostic value for ischemic stroke remains unclear.ObjectivesThe authors aimed to evaluate the combined effects of RC and high-sensitivity C-reactive protein (hs-CRP), as well as a novel index—the remnant cholesterol-inflammation index (RCII)—for long-term clinical outcomes after ischemic stroke.MethodsWe measured RC and hs-CRP levels in 3,008 participants from the China Antihypertensive Trial in Acute Ischemic Stroke. Participants were categorized into 4 groups according to dichotomized RC (≥median, 28.62 mg/dL) and hs-CRP (≥threshold, 2.00 mg/L). RCII was calculated as (RC [mg/dL]×hs-CRP [mg/L])/10 to quantify their joint effects. The study outcomes included all-cause mortality, cardiovascular events, and unfavorable functional outcome at 24 months.ResultsCompared with patients with no residual risk, HRs or ORs for those with residual cholesterol and inflammation risk were 2.33 (95% CI: 1.57-3.44) for all-cause mortality, 2.28 (95% CI: 1.49-3.49) for stroke-specific mortality, and 1.91 (95% CI: 1.44-2.53) for unfavorable functional outcome. In addition, the highest quartile of RCII exhibited increased risks of all-cause mortality, cardiovascular events, and unfavorable functional outcome. Both combined RC/hs-CRP and RCII offered substantial risk discrimination and reclassification improvement for study outcomes beyond traditional risk factors, as evidenced by an increase in C-statistics, net reclassification index, and integrated discrimination improvement.ConclusionsElevated RC and hs-CRP were synergistically associated with increased risks of long-term all-cause mortality and unfavorable functional outcome, and RCII manifested dose-dependent associations with adverse clinical outcomes and superior predictive capacity. Stroke remains a leading contributor to global mortality and chronic disability, posing substantial challenges to public health.1 Despite the proven efficacy of contemporary lipid-lowering therapies in cardiovascular disease (CVD) management and the additional reduction in major adverse cardiovascular events (MACEs) incidence and mortality achieved through anti-inflammatory treatments, a substantial proportion of stroke survivors continue to experience elevated “residual risk.”2,3 Residual cholesterol and inflammation may be important factors driving this residual risk.4 Remnant cholesterol (RC), a triglyceride-rich lipoprotein cholesterol, has been demonstrated to be associated with CVD, CVD mortality, and all-cause mortality.5, 6, 7, 8 Remarkably, elevated levels of RC remain strongly associated with an increased risk of stroke as well as poor poststroke clinical outcomes even under optimal lipid-lowering therapy.9,10 High-sensitivity C-reactive protein (hs-CRP), a marker of inflammation status, has been implicated in stroke recurrence and functional dependence after ischemic stroke through mechanisms such as endothelial dysfunction, plaque destabilization, and prothrombotic activation.11,12 Emerging evidence further indicated that controlled low-density lipoprotein cholesterol (LDL-C) levels combined with low-grade inflammation (eg, elevated hs-CRP) may jointly decrease the risk of MACEs.13, 14, 15 Although the independent prognostic roles of RC and hs-CRP in stroke outcomes have been consistently established,16,17 the combined effect of elevated RC specifically (distinct from LDL-C-controlled residual risk) and persistent inflammation remains uncharacterized in ischemic stroke patients. Recently, a novel composite biomarker termed remnant cholesterol inflammatory index (RCII) has been proposed, calculated as (RC [mg/dL] × hs-CRP [mg/L])/10, which quantified the pathophysiological interplay between residual cholesterol and systemic inflammation. This composite index had shown significant associations with incident stroke or all-cause mortality in middle-aged and elderly populations.18,19 However, little is known about the prognostic value of RCII after acute ischemic stroke. To extend knowledge of dual residual risks of cholesterol and inflammation status on the stroke outcomes, we prospectively explored the joint effects of elevated RC and hs-CRP levels, as well as RCII on all-cause mortality, stroke-specific mortality, cardiovascular events, and unfavorable functional outcome in a large, multicenter cohort of patients with acute ischemic stroke. Methods Study design and participants The present study is a secondary analysis of the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS), a multicenter, single-blind, blinded endpoints, randomized clinical trial conducted in 26 hospitals across China from August 2009 to May 2013. The CATIS evaluated whether immediate blood pressure (BP) reduction in acute ischemic stroke patients reduces death and major disability at 14 days or hospital discharge.20 Patients with a BP ≥220/120 mm Hg, severe heart failure, acute myocardial infarction or unstable angina, atrial fibrillation, aortic dissection, cerebrovascular stenosis, or resistant hypertension; those in a deep coma; and those who were treated with intravenous thrombolytic therapy were excluded from the CATIS trial. In the present study, we further excluded 1,063 participants without data of RC and hs-CRP levels or loss to follow-up, resulting in a final analytic sample of 3,008 patients (Supplemental Figure 1). Most baseline characteristics of enrolled and excluded patients in this analysis were well-balanced (Supplemental Table 1). This study was approved by Institutional Review Boards at Soochow University, Tulane University, and all participating hospitals. Written informed consent was obtained from all participants or their immediate family members. Data collection Baseline data on demographic characteristics, medication history, and clinical features were collected upon enrollment. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS).21 Based on symptoms and imaging data of the patients, ischemic stroke was classified as large artery atherosclerosis, cardiac embolism, and small artery occlusion.22 Trained nurses recorded 3 BP measurements at baseline using a standard mercury sphygmomanometer with patients in the supine position. The mean of the 3 BP records was used in analyses. In each participating hospital, blood samples were collected after at least 8 hours of fasting within 24 hours of patients’ hospital admission. Serum and plasma samples were separated at clinical laboratories of the participating hospitals and immediately frozen at −80 °C until testing. Serum hs-CRP concentrations were measured using commercially available immunoassays (R&D Systems). Routine laboratory analyses including blood glucose, blood lipids, and platelet count were conducted at participating hospitals during the initial assessment. Assessment of study outcome Participants were followed up in person at 24 months after acute ischemic stroke by trained neurologists who were unaware of baseline characteristics and treatment assignment. The study outcomes included all-cause mortality, stroke-specific mortality, cardiovascular events (ie, cardiovascular deaths, nonfatal myocardial infarction, hospitalized and treated angina, hospitalized and treated congestive heart failure, and hospitalized and treated peripheral arterial disease), and unfavorable functional outcome. Unfavorable functional outcome was the combination of death and major disability, defined as a modified Rankin Scale (mRS) score ≥3. The mRS scores range from 0 (no symptoms) to 6 (death), with scores ≥3 indicating functional impairment impacting independent daily living.20 Death certificates were obtained for deceased patients, and hospital data were abstracted for stroke recurrence and cardiovascular events. A trial-wide outcomes assessment committee, blinded to treatment assignment, reviewed and adjudicated subsequent outcomes. Statistical analysis Participants were first categorized into 4 mutually exclusive groups according to dichotomized RC (≥median, 28.62 mg/dL) and hs-CRP (≥threshold, 2.00 mg/L) at baseline: no residual risk, residual cholesterol risk (RCR) only, residual inflammation risk (RIR) only, and residual cholesterol and inflammation risk (RCIR).13,23 The data were expressed as median (IQR) for continuous variables and frequency (percentage) for categorical variables. Continuous variables were analyzed using the Kruskal-Wallis test, while Cochran-Armitage trend chi-square test was applied for categorical variables. The cumulative incidence of all-cause mortality and cardiovascular events according to RC and hs-CRP levels was assessed with Kaplan-Meier curves and compared by log-rank tests. The associations between baseline residual risk groups (no residual risk, RCR, RIR, RCIR) and study outcomes were evaluated using Cox proportional hazards regression and logistic regression models, with HRs, ORs, and 95% CIs calculated. The proportional hazards assumption of the Cox models was tested using Schoenfeld residuals, which showed no significant departure from proportionality (P > 0.05). Multivariable models adjusted for covariates including age, sex, body mass index, time from onset to randomization, current alcohol drinking, current smoking, systolic BP, triglycerides, fasting plasma glucose (FPG), admission NIHSS score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, estimated glomerular filtration rate, and ischemic stroke subtype. The covariates for multivariable adjustment were selected based on prior knowledge and the differences in baseline characteristics, no significant multicollinearity was observed according to the variance inflation factors.24 In addition, we further explored the relationships between RCII levels and clinical outcomes. Restricted cubic spline models were used to provide more precise estimates and to explore the potential nonlinear relationships between RCII and clinical outcomes with 3 knots (at the 5th, 50th, and 95th percentiles), and the 2.5% highest and lowest RCII values were trimmed to minimize the potential influence of outliers. The Fine-Gray model was performed as a sensitivity analysis to robustly assess the association between RCII levels and cardiovascular events (excluding vascular death) by regarding death as a competing risk. To evaluate the incremental predictive value of RCII or combined RC/hs-CRP variables beyond established risk factors, a basic model containing conventional predictors was compared against enhanced models incorporating either RCII or combined RC and hs-CRP. The Hosmer Lemeshow chi-square statistic was applied to evaluate the calibration of models with RCII or combined RC and hs-CRP. C-statistics, the net reclassification index (NRI), and integrated discrimination improvement (IDI) were calculated to evaluate improvements in risk discrimination and reclassification when adding either RCII or combined RC and hs-CRP to the basic model. Markov chain Monte Carlo methods were conducted to perform multiple imputations for missing covariate data. Five imputed data sets were generated, and the averaged values were used for the analyses. All statistical tests were 2-sided, with P < 0.05 considered statistically significant. Analyses used SAS version 9.4 (SAS Institute). Results Baseline characteristics A total of 3,008 patients (1,911 men and 1,097 women) with acute ischemic stroke were included in the final analysis. Baseline characteristics were compared across groups defined by the combined RC/hs-CRP variable or across quartiles of RCII. Of all patients, 798 (26.5%) had no residual risk, 701 (23.3%) had RIR, 729 (24.2%) had RCR, and 780 (25.9%) had RCIR. Patients with RCIR displayed the most adverse metabolic profile with the highest body mass index, FPG, and triglyceride level, alongside the lowest high-density lipoprotein cholesterol. In addition, patients with RCIR had the highest prevalence of diabetes and hypertension. Patients with RCR only were younger and had the highest total cholesterol level, while the RIR group had the oldest patients and highest admission NIHSS score (Supplemental Table 2). Compared with patients in the lowest quartile of RCII, those with higher RCII were more likely to be older and female; to have higher level of triglyceride, total cholesterol, FPG, LDL-C, admission systolic BP, NIHSS score; to have higher prevalence of hypertension and diabetes; and to have higher proportion of antihypertensive medication use and cardiac embolism stroke subtypes (Table 1).Table 1Baseline Characteristics at the RCII LevelsRCIIP ValueQuartile 1 (<1.72) (n = 755)Quartile 2 (1.72-5.15) (n = 749)Quartile 3 (5.15-16.46) (n = 752)Quartile 4 (≥16.46) (n = 752)Demographic Age, y60 (53.0-68.0)61.0 (54.0-69.0)61.0 (55.0-69.0)64.0 (56.0-73.0)<0.001 Male, n (%)504 (66.75)490 (65.42)467 (62.10)450 (59.84)0.02 BMI, kg/m224.2 (22.6-26.0)24.8 (22.9-26.8)24.9 (23.0-26.8)25.1 (23.0-27.5)<0.001 Current smoking310 (41.06)277 (36.98)281 (37.37)286 (38.03)0.39 Current alcohol drinking255 (33.77)258 (34.45)230 (30.59)204 (27.13)0.01Clinical features Time from onset to randomization, h12.0 (5.0-24.0)11.0 (5.0-24.0)10.0 (4.0-24.0)10.0 (4.0-24.0)0.15 Triglyceride, mmol/L1.2 (0.9-1.7)1.5 (1.0-2.0)1.6 (1.1-2.3)1.7 (1.2-2.6)<0.001 Total cholesterol, mmol/L4.7 (4.0-5.4)5.0 (4.3-5.6)5.2 (4.5-5.8)5.3 (4.5-6.1)<0.001 LDL-C, mmol/L2.7 (2.2-3.3)2.8 (2.3-3.4)3.0 (2.4-3.6)2.8 (2.2-3.4)<0.001 HDL-C, mmol/L1.3 (1.1-1.6)1.2 (1.0-1.5)1.2 (1.0-1.4)1.2 (1.0-1.4)<0.001 FPG, mmol/L5.5 (4.9-6.6)5.7 (5.0-6.9)5.9 (5.1-7.3)6.1 (5.3-8.1)<0.001 Admission systolic BP, mm Hg160.7 (151.3-176.0)162.0 (153.3-176.7)162.7 (152.0-178.7)166.7 (154.7-179.3)0.005 Admission diastolic BP, mm Hg96.7 (90.0-100.7)98.0 (90.0-100.7)98.7 (90.0-101.3)98.0 (90.0-100.7)0.41 eGFR, mL/min/1.73 m2107.2 (94.0-116.3)106.3 (94.8-115.4)105.4 (94.5-115.0)102.5 (89.1-113.1)<0.001 Admission NIHSS score4 (2-7)4 (2-7)5 (3-8)6 (3-10)<0.001Medical history Hypertension573 (75.89)592 (79.04)618 (82.18)603 (80.19)0.02 Hyperlipidemia50 (6.75)45 (6.41)64 (8.51)50 (6.65)0.37 Diabetes mellitus121 (16.03)125 (16.69)137 (18.22)159 (21.14)0.05 Coronary heart disease77 (10.20)67 (8.95)81 (10.77)97 (12.90)0.09Medication at baseline Antihypertensive326 (43.18)369 (49.27)382 (50.80)399 (53.06)0.001 Lipid lowering16 (2.12)21 (2.80)32 (4.26)24 (3.19)0.11Ischemic stroke subtype (%) Large artery atherosclerosis563 (74.57)587 (78.37)591 (78.59)547 (72.74)0.52 Cardiac embolism32 (4.24)30 (4.01)29 (3.86)63 (8.38)<0.001 Small artery occlusion160 (21.19)132 (17.62)132 (17.55)142 (18.88)0.30BP = blood pressure; BMI = body mass index; eGFR = estimated glomerular filtration rate; FPG = fasting plasma glucose; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; NIHSS = National Institutes of Health Stroke Scale; RCII = remnant cholesterol inflammatory index.Values are median (IQR) or n (%). Table 1Baseline Characteristics at the RCII LevelsRCIIP ValueQuartile 1 (<1.72) (n = 755)Quartile 2 (1.72-5.15) (n = 749)Quartile 3 (5.15-16.46) (n = 752)Quartile 4 (≥16.46) (n = 752)Demographic Age, y60 (53.0-68.0)61.0 (54.0-69.0)61.0 (55.0-69.0)64.0 (56.0-73.0)<0.001 Male, n (%)504 (66.75)490 (65.42)467 (62.10)450 (59.84)0.02 BMI, kg/m224.2 (22.6-26.0)24.8 (22.9-26.8)24.9 (23.0-26.8)25.1 (23.0-27.5)<0.001 Current smoking310 (41.06)277 (36.98)281 (37.37)286 (38.03)0.39 Current alcohol drinking255 (33.77)258 (34.45)230 (30.59)204 (27.13)0.01Clinical features Time from onset to randomization, h12.0 (5.0-24.0)11.0 (5.0-24.0)10.0 (4.0-24.0)10.0 (4.0-24.0)0.15 Triglyceride, mmol/L1.2 (0.9-1.7)1.5 (1.0-2.0)1.6 (1.1-2.3)1.7 (1.2-2.6)<0.001 Total cholesterol, mmol/L4.7 (4.0-5.4)5.0 (4.3-5.6)5.2 (4.5-5.8)5.3 (4.5-6.1)<0.001 LDL-C, mmol/L2.7 (2.2-3.3)2.8 (2.3-3.4)3.0 (2.4-3.6)2.8 (2.2-3.4)<0.001 HDL-C, mmol/L1.3 (1.1-1.6)1.2 (1.0-1.5)1.2 (1.0-1.4)1.2 (1.0-1.4)<0.001 FPG, mmol/L5.5 (4.9-6.6)5.7 (5.0-6.9)5.9 (5.1-7.3)6.1 (5.3-8.1)<0.001 Admission systolic BP, mm Hg160.7 (151.3-176.0)162.0 (153.3-176.7)162.7 (152.0-178.7)166.7 (154.7-179.3)0.005 Admission diastolic BP, mm Hg96.7 (90.0-100.7)98.0 (90.0-100.7)98.7 (90.0-101.3)98.0 (90.0-100.7)0.41 eGFR, mL/min/1.73 m2107.2 (94.0-116.3)106.3 (94.8-115.4)105.4 (94.5-115.0)102.5 (89.1-113.1)<0.001 Admission NIHSS score4 (2-7)4 (2-7)5 (3-8)6 (3-10)<0.001Medical history Hypertension573 (75.89)592 (79.04)618 (82.18)603 (80.19)0.02 Hyperlipidemia50 (6.75)45 (6.41)64 (8.51)50 (6.65)0.37 Diabetes mellitus121 (16.03)125 (16.69)137 (18.22)159 (21.14)0.05 Coronary heart disease77 (10.20)67 (8.95)81 (10.77)97 (12.90)0.09Medication at baseline Antihypertensive326 (43.18)369 (49.27)382 (50.80)399 (53.06)0.001 Lipid lowering16 (2.12)21 (2.80)32 (4.26)24 (3.19)0.11Ischemic stroke subtype (%) Large artery atherosclerosis563 (74.57)587 (78.37)591 (78.59)547 (72.74)0.52 Cardiac embolism32 (4.24)30 (4.01)29 (3.86)63 (8.38)<0.001 Small artery occlusion160 (21.19)132 (17.62)132 (17.55)142 (18.88)0.30BP = blood pressure; BMI = body mass index; eGFR = estimated glomerular filtration rate; FPG = fasting plasma glucose; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; NIHSS = National Institutes of Health Stroke Scale; RCII = remnant cholesterol inflammatory index.Values are median (IQR) or n (%). Baseline Characteristics at the RCII Levels BP = blood pressure; BMI = body mass index; eGFR = estimated glomerular filtration rate; FPG = fasting plasma glucose; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; NIHSS = National Institutes of Health Stroke Scale; RCII = remnant cholesterol inflammatory index. Values are median (IQR) or n (%). Combined effects of residual cholesterol and inflammation on stroke outcomes Over a 24-month follow-up, a total of 251 patients (8.34%) experienced all-cause mortality (202 were stroke-specific mortality), 275 (9.14%) developed cardiovascular events, and 680 (23.73%) had an unfavorable functional outcome. Kaplan-Meier analysis revealed significant differences in the cumulative incidence of all-cause mortality, cardiovascular events, and the composite outcome of cardiovascular events and all-cause mortality among the 4 groups: no residual risk, RCR, RIR, and RCIR (all log-rank P < 0.01) (Figures 1A to 1C). After adjustment for potential confounders, patients with RCIR had significantly higher risks of all-cause mortality (HR: 2.33; 95% CI: 1.57-3.44), stroke-specific mortality (HR: 2.28; 95% CI: 1.49-3.49), the composite outcome of cardiovascular events and all-cause mortality (HR: 1.66; 95% CI: 1.25-2.20), and unfavorable functional outcome (OR: 1.91; 95% CI: 1.44-2.53), compared to those with no residual risk (Figure 2). Furthermore, RIR was independently associated with all-cause mortality (HR: 1.72; 95% CI: 1.17-2.54), the composite outcome of cardiovascular events and all-cause mortality (HR: 1.33; 95% CI: 1.01-1.75), and unfavorable functional outcome (OR: 1.79; 95% CI: 1.36-2.35). In contrast, no significant associations were observed between the RCR group and any clinical outcomes. In multivariable ordinal logistic regression analysis, the adjusted OR for a worse shift in mRS score in patients with concomitant elevation of RC and hs-CRP (RCIR) was 1.39 (95% CI: 1.14-1.71; P for trend <0.001) (Figure 3A). However, there was no significant additive interaction between RC and hs-CRP on stroke outcomes (Supplemental Table 3).Figure 1Kaplan-Meier Curves for Cumulative Incidence of Stroke Outcomes, Stratified by Combined Remnant Cholesterol and High-Sensitivity C-Reactive Protein Levels and RCII Level(A to C) Stratified by combined remnant cholesterol and high-sensitivity C-reactive protein levels; (D to F) Stratified by RCII levels. RCIR = residual cholesterol and inflammation risk; RCR = residual cholesterol risk; RIR = residual inflammation risk.Figure 2Association of Combined Remnant Cholesterol and High-Sensitivity C-Reactive Protein With Risk of Stroke OutcomesHRs or ORs were adjusted for age, sex, body mass index, time from onset to randomization, current alcohol drinking, current smoking, systolic blood pressure, triglycerides, fasting plasma glucose, admission National Institutes of Health Stroke Scale score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, estimated glomerular filtration rate, and ischemic stroke subtype. Logistic regression model was used for unfavorable functional outcome. Abbreviations as in Figure 1.Figure 3Distribution of Modified Rankin Scale Scores Stratified by Combined Remnant Cholesterol and High-Sensitivity C-Reactive Protein Categories and RCII LevelAdjusted OR of ordinal logistic regression analysis is 1.39 (95% CI: 1.14-1.71, P for trend <0.001) for residual cholesterol and inflammation risk, and 1.65 (95% CI: 1.36-2.01, P for trend <0.001) for highest vs lowest quartile of RCII. (A) stratified by combined RC and hs-CRP levels (B) stratified by RCII levels. hs-CRP = high-sensitivity C-reactive protein; hs-RCII = remnant cholesterol inflammatory index; mRS = modified Rankin Scale; RC = remnant cholesterol; other abbreviations as in Figure 1. Kaplan-Meier Curves for Cumulative Incidence of Stroke Outcomes, Stratified by Combined Remnant Cholesterol and High-Sensitivity C-Reactive Protein Levels and RCII Level (A to C) Stratified by combined remnant cholesterol and high-sensitivity C-reactive protein levels; (D to F) Stratified by RCII levels. RCIR = residual cholesterol and inflammation risk; RCR = residual cholesterol risk; RIR = residual inflammation risk. Association of Combined Remnant Cholesterol and High-Sensitivity C-Reactive Protein With Risk of Stroke Outcomes HRs or ORs were adjusted for age, sex, body mass index, time from onset to randomization, current alcohol drinking, current smoking, systolic blood pressure, triglycerides, fasting plasma glucose, admission National Institutes of Health Stroke Scale score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, estimated glomerular filtration rate, and ischemic stroke subtype. Logistic regression model was used for unfavorable functional outcome. Abbreviations as in Figure 1. Distribution of Modified Rankin Scale Scores Stratified by Combined Remnant Cholesterol and High-Sensitivity C-Reactive Protein Categories and RCII Level Adjusted OR of ordinal logistic regression analysis is 1.39 (95% CI: 1.14-1.71, P for trend <0.001) for residual cholesterol and inflammation risk, and 1.65 (95% CI: 1.36-2.01, P for trend <0.001) for highest vs lowest quartile of RCII. (A) stratified by combined RC and hs-CRP levels (B) stratified by RCII levels. hs-CRP = high-sensitivity C-reactive protein; hs-RCII = remnant cholesterol inflammatory index; mRS = modified Rankin Scale; RC = remnant cholesterol; other abbreviations as in Figure 1. Association between RCII and stroke outcomes Figure 1 shows the Kaplan-Meier curves for cumulative incidences of stroke outcomes across RCII quartiles. Patients in the highest quartile of RCII had higher cumulative incidence of all-cause mortality (log-rank P < 0.001), as well as cardiovascular events (log-rank P = 0.022) and the composite outcome of all-cause mortality or cardiovascular events (log-rank P < 0.001). The highest quartile presented with significantly increased risks for all-cause mortality (HR: 3.05; 95% CI: 2.06-4.53), stroke-specific mortality (HR: 2.99; 95% CI: 1.94-4.61), cardiovascular events (HR: 1.45; 95% CI: 1.03-2.05), and unfavorable functional outcome (OR: 2.14; 95% CI: 1.62-2.83) compared with lowest quartile. Per 1-SD increase in log-transformed RCII was significantly associated with increased risk of all study outcomes, with HRs/ORs ranging from 1.16 to 1.76 (all P < 0.01) (Table 2). The subgroup analyses showed that ischemic stroke subtype did not modify the associations between RCII and study clinical outcomes (all P for interaction >0.05), with the significant findings across most groups (Supplemental Table 4). In a competing risk analysis treating death as a competing event, elevated RCII levels remained significantly associated with cardiovascular events after ischemic stroke (Supplemental Table 5).Table 2Risk of Clinical Outcomes by Quartiles of RCII in Patients With Ischemic StrokeRCIIP Value for TrendEach 1-SD Increase of log RCIIQuartile 1Quartile 2Quartile 3Quartile 4All-cause mortality Event, n (%)34 (4.50)36 (4.81)58 (7.71)123 (16.36)251 (8.34) Age- and sex-adjusted HR1.00 (ref.)0.97 (0.61-1.55)1.59 (1.04-2.43)3.21 (2.19-4.70)<0.0011.78 (1.56-2.03) Multiple-adjusted HRa1.00 (ref.)0.95 (0.59-1.52)1.50 (0.98-2.31)3.05 (2.06-4.53)<0.0011.75 (1.52-2.01)Stroke-specific mortality Event, n (%)28 (3.71)28 (3.74)41 (5.45)105 (13.96)202 (6.72) Age- and sex-adjusted HR1.00 (ref.)0.91 (0.54-1.53)1.34 (0.82-2.17)3.26 (2.14-4.96)<0.0011.83 (1.58-2.12) Multiple-adjusted HR1.00 (ref.)0.87 (0.51-1.49)1.23 (0.75-2.02)2.99 (1.94-4.61)<0.0011.76 (1.51-2.05)Cardiovascular events Event, n (%)63 (8.34)65 (8.68)61 (8.11)86 (11.44)275 (9.14) Age- and sex-adjusted HR1.00 (ref.)1.00 (0.70-1.41)0.97 (0.68-1.38)1.42 (1.02-1.97)0.0061.15 (1.01-1.30) Multiple-adjusted HR1.00 (ref.)0.98 (0.69-1.39)0.97 (0.68-1.39)1.45 (1.03-2.05)0.0041.16 (1.02-1.32)All-cause mortality and cardiovascular events Event, n (%)78 (10.33)85 (11.35)95 (12.63)163 (21.68)421 (14.00) Age- and sex-adjusted HR1.00 (ref.)1.02 (0.75-1.39)1.20 (0.86-1.62)2.04 (1.56-2.68)<0.0011.40 (1.26-1.55) Multiple-adjusted HR1.00 (ref.)1.02 (0.75-1.39)1.17 (0.87-1.59)2.02 (1.52-2.69)<0.0011.39 (1.25-1.55)Unfavorable functional outcome (death or major disabilityb) Event, n (%)119 (16.64)133 (18.32)169 (23.60)259 (36.53)680 (23.73) Age- and sex-adjusted OR1.00 (ref.)1.08 (0.82-1.43)1.51 (1.16-1.98)2.53 (1.96-3.27)<0.0011.51 (1.37-2.25) Multiple-adjusted ORa1.00 (ref.)1.06 (0.79-1.42)1.35 (1.01-1.80)2.14 (1.62-2.83)<0.0011.40 (1.26-1.56)Abbreviations as in Table 1.aAdjusted for age, sex, BMI, time from onset to randomization, current alcohol drinking, current smoking, systolic BP, triglycerides, FPG, admission NIHSS score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, eGFR, and ischemic stroke subtype.bDeath or major disability: modified Rankin Scale score ≥3; logistic regression model was used. Table 2Risk of Clinical Outcomes by Quartiles of RCII in Patients With Ischemic StrokeRCIIP Value for TrendEach 1-SD Increase of log RCIIQuartile 1Quartile 2Quartile 3Quartile 4All-cause mortality Event, n (%)34 (4.50)36 (4.81)58 (7.71)123 (16.36)251 (8.34) Age- and sex-adjusted HR1.00 (ref.)0.97 (0.61-1.55)1.59 (1.04-2.43)3.21 (2.19-4.70)<0.0011.78 (1.56-2.03) Multiple-adjusted HRa1.00 (ref.)0.95 (0.59-1.52)1.50 (0.98-2.31)3.05 (2.06-4.53)<0.0011.75 (1.52-2.01)Stroke-specific mortality Event, n (%)28 (3.71)28 (3.74)41 (5.45)105 (13.96)202 (6.72) Age- and sex-adjusted HR1.00 (ref.)0.91 (0.54-1.53)1.34 (0.82-2.17)3.26 (2.14-4.96)<0.0011.83 (1.58-2.12) Multiple-adjusted HR1.00 (ref.)0.87 (0.51-1.49)1.23 (0.75-2.02)2.99 (1.94-4.61)<0.0011.76 (1.51-2.05)Cardiovascular events Event, n (%)63 (8.34)65 (8.68)61 (8.11)86 (11.44)275 (9.14) Age- and sex-adjusted HR1.00 (ref.)1.00 (0.70-1.41)0.97 (0.68-1.38)1.42 (1.02-1.97)0.0061.15 (1.01-1.30) Multiple-adjusted HR1.00 (ref.)0.98 (0.69-1.39)0.97 (0.68-1.39)1.45 (1.03-2.05)0.0041.16 (1.02-1.32)All-cause mortality and cardiovascular events Event, n (%)78 (10.33)85 (11.35)95 (12.63)163 (21.68)421 (14.00) Age- and sex-adjusted HR1.00 (ref.)1.02 (0.75-1.39)1.20 (0.86-1.62)2.04 (1.56-2.68)<0.0011.40 (1.26-1.55) Multiple-adjusted HR1.00 (ref.)1.02 (0.75-1.39)1.17 (0.87-1.59)2.02 (1.52-2.69)<0.0011.39 (1.25-1.55)Unfavorable functional outcome (death or major disabilityb) Event, n (%)119 (16.64)133 (18.32)169 (23.60)259 (36.53)680 (23.73) Age- and sex-adjusted OR1.00 (ref.)1.08 (0.82-1.43)1.51 (1.16-1.98)2.53 (1.96-3.27)<0.0011.51 (1.37-2.25) Multiple-adjusted ORa1.00 (ref.)1.06 (0.79-1.42)1.35 (1.01-1.80)2.14 (1.62-2.83)<0.0011.40 (1.26-1.56)Abbreviations as in Table 1.aAdjusted for age, sex, BMI, time from onset to randomization, current alcohol drinking, current smoking, systolic BP, triglycerides, FPG, admission NIHSS score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, eGFR, and ischemic stroke subtype.bDeath or major disability: modified Rankin Scale score ≥3; logistic regression model was used. Risk of Clinical Outcomes by Quartiles of RCII in Patients With Ischemic Stroke Abbreviations as in Table 1. Adjusted for age, sex, BMI, time from onset to randomization, current alcohol drinking, current smoking, systolic BP, triglycerides, FPG, admission NIHSS score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, eGFR, and ischemic stroke subtype. Death or major disability: modified Rankin Scale score ≥3; logistic regression model was used. Multivariable-adjusted restricted cubic spline analyses demonstrated that RCII levels were associated with study outcomes, with nonlinear relationships for all-cause mortality, composite outcome of cardiovascular events and all-cause mortality, and unfavorable functional outcome (all P for nonlinearity <0.01) (Central Illustration, Figure 4). Multivariable ordinal logistic regression analyses showed a significantly worse shift in the distribution of mRS score with higher RCII quartiles in acute ischemic stroke patients (P for trend <0.001) (Figure 3B).Figure 4Relationships Between RCII Levels and Study Outcomes in Patients With Acute Ischemic Stroke(A) Cardiovascular events; (B) Composite outcome of cardiovascular events and all-cause mortality; (C) Unfavorable functional outcome. HRs or ORs and 95% CIs derived from restricted cubic spline regression, with knots placed at the 5th, 50th, and 95th percentiles of the distribution of RCII levels. The reference point corresponds to the 25th percentile of RCII levels. HRs or ORs were adjusted for the same variables in Figure 2. Abbreviation as in Figure 3.Central IllustrationImpacts of Remnant Cholesterol and Residual Inflammation on Clinical Outcomes After Ischemic StrokeAbbreviations as in Figures 1 and 3. Relationships Between RCII Levels and Study Outcomes in Patients With Acute Ischemic Stroke (A) Cardiovascular events; (B) Composite outcome of cardiovascular events and all-cause mortality; (C) Unfavorable functional outcome. HRs or ORs and 95% CIs derived from restricted cubic spline regression, with knots placed at the 5th, 50th, and 95th percentiles of the distribution of RCII levels. The reference point corresponds to the 25th percentile of RCII levels. HRs or ORs were adjusted for the same variables in Figure 2. Abbreviation as in Figure 3. Impacts of Remnant Cholesterol and Residual Inflammation on Clinical Outcomes After Ischemic Stroke Abbreviations as in Figures 1 and 3. Incremental predictive value of residual cholesterol and inflammation status We further evaluated the incremental predictive value of RC combined with hs-CRP and RCII for stroke prognosis. Adding either RC combined with hs-CRP or RCII to a basic model significantly improved risk reclassification and discriminatory ability for all-cause mortality. The C-statistic of the basic model including conventional risk factors increased from 0.778 to 0.791 after adding RC and hs-CRP (P < 0.001), and from 0.778 to 0.786 after adding RCII (P = 0.001); the corresponding category-free NRI values were 24.7% (95% CI: 12.3%-37.1%; P < 0.001) and 19.0% (95% CI: 6.6%-31.3%; P < 0.001), and IDI values were 1.5% and 0.9%, respectively (both P < 0.001). The Hosmer–Lemeshow test indicated that model calibration was adequate (Supplemental Figure 2). Similar predictive significance was observed for stroke-specific mortality and unfavorable functional outcome but not for cardiovascular events (Table 3).Table 3Assessment of Predictive Model Performance for Stroke OutcomesC-StatisticsCategory-Free NRI (%)IDI (%)CalibrationEstimate (95% CI)P ValueEstimate (95% CI)P ValueEstimate (95% CI)P ValueChi-SquareP ValueAll-cause mortality Basic modela0.778 (0.750-0.808)ReferenceReference9.90.27 Basic model + RC + hs-CRPb0.791 (0.761-0.821)<0.00124.7 (12.3-37.1)<0.0011.5 (0.1-2.4)0.00111.70.17 Basic model + RCII0.786 (0.758-0.816)0.00119.0 (6.6-31.3)0.0040.9 (0.1-1.7)0.039.70.29Stroke-specific mortality Basic model0.802 (0.772-0.832)ReferenceReference8.40.40 Basic model + RC + hs-CRP0.815 (0.785-0.844)0.00124.3 (10.5-38.2)<0.0011.7 (0.1-2.8)0.0029.20.32 Basic model + RCII0.811 (0.782-0.841)0.00115.5 (1.8-29.1)0.031.1 (0.1-2.1)0.035.60.69Cardiovascular events Basic model0.606 (0.572-0.641)ReferenceReference4.50.81 Basic model + RC + hs-CRP0.611 (0.572-0.641)0.2514.4 (2.4-26.3)0.020.09 (−0.01 to 0.2)0.094.20.84 Basic model + RCII0.607 (0.573-0.641)0.73−5.5 (−16.3 to 5.4)0.390.00 (−0.02 to 0.03)0.548.20.41All-cause mortality and cardiovascular events Basic model0.680 (0.652-0.709)ReferenceReference12.80.12 Basic model + RC + hs-CRP0.689 (0.660-0.717)0.018.8 (−0.7 to 18.4)0.090.7 (0.3-1.2)0.00215.50.05 Basic model + RCII0.685 (0.657-0.713)0.0212.2 (2.7-21.7)0.020.4 (0.0-0.8)0.0511.50.17Unfavorable functional outcome (death or major disabilityc) Basic model0.764 (0.745-0.784)ReferenceReference4.10.85 Basic model + RC + hs-CRP0.774 (0.745-0.784)<0.00120.5 (12.3-28.8)<0.0011.9 (1.2-2.5)<0.0014.10.85 Basic model + RCII0.769 (0.749-0.789)0.0122.0 (14.6-29.4)<0.0010.9 (0.5-1.4)<0.0013.00.94hs-CRP = high-sensitivity C-reactive protein; IDI = integrated discrimination improvement; NRI = net reclassification index; RC = remnant cholesterol; other abbreviations as in Table 1.aBasic model included: age, sex, BMI, time from onset to randomization, current alcohol drinking, current smoking, systolic BP, triglycerides, FPG, admission NIHSS score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, eGFR, and ischemic stroke subtype.bRC and hs-CRP as continuous variables.cDeath or major disability: modified Rankin Scale score ≥3. Table 3Assessment of Predictive Model Performance for Stroke OutcomesC-StatisticsCategory-Free NRI (%)IDI (%)CalibrationEstimate (95% CI)P ValueEstimate (95% CI)P ValueEstimate (95% CI)P ValueChi-SquareP ValueAll-cause mortality Basic modela0.778 (0.750-0.808)ReferenceReference9.90.27 Basic model + RC + hs-CRPb0.791 (0.761-0.821)<0.00124.7 (12.3-37.1)<0.0011.5 (0.1-2.4)0.00111.70.17 Basic model + RCII0.786 (0.758-0.816)0.00119.0 (6.6-31.3)0.0040.9 (0.1-1.7)0.039.70.29Stroke-specific mortality Basic model0.802 (0.772-0.832)ReferenceReference8.40.40 Basic model + RC + hs-CRP0.815 (0.785-0.844)0.00124.3 (10.5-38.2)<0.0011.7 (0.1-2.8)0.0029.20.32 Basic model + RCII0.811 (0.782-0.841)0.00115.5 (1.8-29.1)0.031.1 (0.1-2.1)0.035.60.69Cardiovascular events Basic model0.606 (0.572-0.641)ReferenceReference4.50.81 Basic model + RC + hs-CRP0.611 (0.572-0.641)0.2514.4 (2.4-26.3)0.020.09 (−0.01 to 0.2)0.094.20.84 Basic model + RCII0.607 (0.573-0.641)0.73−5.5 (−16.3 to 5.4)0.390.00 (−0.02 to 0.03)0.548.20.41All-cause mortality and cardiovascular events Basic model0.680 (0.652-0.709)ReferenceReference12.80.12 Basic model + RC + hs-CRP0.689 (0.660-0.717)0.018.8 (−0.7 to 18.4)0.090.7 (0.3-1.2)0.00215.50.05 Basic model + RCII0.685 (0.657-0.713)0.0212.2 (2.7-21.7)0.020.4 (0.0-0.8)0.0511.50.17Unfavorable functional outcome (death or major disabilityc) Basic model0.764 (0.745-0.784)ReferenceReference4.10.85 Basic model + RC + hs-CRP0.774 (0.745-0.784)<0.00120.5 (12.3-28.8)<0.0011.9 (1.2-2.5)<0.0014.10.85 Basic model + RCII0.769 (0.749-0.789)0.0122.0 (14.6-29.4)<0.0010.9 (0.5-1.4)<0.0013.00.94hs-CRP = high-sensitivity C-reactive protein; IDI = integrated discrimination improvement; NRI = net reclassification index; RC = remnant cholesterol; other abbreviations as in Table 1.aBasic model included: age, sex, BMI, time from onset to randomization, current alcohol drinking, current smoking, systolic BP, triglycerides, FPG, admission NIHSS score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, eGFR, and ischemic stroke subtype.bRC and hs-CRP as continuous variables.cDeath or major disability: modified Rankin Scale score ≥3. Assessment of Predictive Model Performance for Stroke Outcomes hs-CRP = high-sensitivity C-reactive protein; IDI = integrated discrimination improvement; NRI = net reclassification index; RC = remnant cholesterol; other abbreviations as in Table 1. Basic model included: age, sex, BMI, time from onset to randomization, current alcohol drinking, current smoking, systolic BP, triglycerides, FPG, admission NIHSS score, medical history (hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease), use of antihypertensive medications, use of lipid-lowering agents, eGFR, and ischemic stroke subtype. RC and hs-CRP as continuous variables. Death or major disability: modified Rankin Scale score ≥3. Discussion In this multicenter prospective cohort study encompassing 3,008 patients with acute ischemic stroke, we first systematically investigated the combined prognostic influence of RC and hs-CRP following ischemic stroke. Patients with RCIR exhibited significantly elevated risks of all-cause mortality, stroke-specific mortality as well as unfavorable functional outcome compared to those without either risk factors. We further identified that the composite index of RC and systemic inflammation, RCII was associated with all-cause mortality, stroke-specific mortality, and unfavorable functional outcome (Central Illustration). In addition, the composite RCII index demonstrated superior predictive ability over conventional risk factors, with significant improvement in both risk discrimination and reclassification for all-cause mortality and unfavorable functional outcome. Our study suggested that dysregulated cholesterol metabolism and systemic inflammation may jointly contribute to adverse poststroke outcomes, highlighting the potential significance of simultaneously implementing lipid-lowering and anti-inflammatory therapeutic strategies to improve clinical outcomes in patients with ischemic stroke. The inflammatory mechanism serves as the core link connecting lipid abnormalities with plaque formation.25 Abnormal lipid metabolism (eg, residual cholesterol retention) and chronic vascular inflammation are not isolated events but interact through oxidative stress and endothelial dysfunction, forming a self-reinforcing cycle that collectively drives plaque formation and rupture.26,27 These interconnected mechanisms collectively suggest that the combined effect of residual cholesterol and inflammation status operates through complementary pathological pathways, thereby exacerbating cardiovascular and cerebrovascular risks. A secondary analysis of the Cardiovascular Inflammation Reduction Trial revealed that the highest absolute risks of MACEs were observed among patients with elevated levels of both cholesterol and inflammation.28 The Kailuan cohort (n = 3,509 statin-treated patients) documented that individuals with combined residual cholesterol and inflammatory risk had 1.75-fold increased all-cause mortality after CVD, compared to those without residual risks.4 Moreover, the Third China National Stroke Registry study showed that residual inflammatory risk independently predicted 1-year stroke recurrence, particularly in atherosclerotic subtypes with stricter LDL-C control in patients with acute ischemic stroke/transient ischemic attack.29 More importantly, patients with combined residual cholesterol (LDL-C ≥2.6 mmol/L) and inflammation exhibited 47% higher composite vascular risk vs controls, supporting synergistic atherogenic effects.29 Elevated RC was reported to be causally associated with low-grade inflammation and ischemic heart disease, whereas elevated LDL cholesterol is associated causally with ischemic heart disease without inflammation.30 A recent cohort study of 104,427 individuals reported that triglyceride-rich lipoproteins (ie, RC) rather than LDL cholesterol constitute a primary driver of atherosclerotic CVD in chronic kidney disease, explaining 25% of excess atherosclerotic CVD risk in statin-treated chronic kidney disease patients.31 Moreover, the Copenhagen Mendelian randomization study of 60,608 participants demonstrated that genetically elevated RC causally increased hs-CRP levels by 28%, establishing a direct inflammatory effect of RC through hs-CRP-mediated pathways. This RC-inflammation synergy highlights a dual-pathogenic mechanism: RC not only drives lipid deposition but also amplifies vascular inflammation, creating a self-reinforcing cycle that accelerates atherosclerosis.30 Therefore, we used RC instead of the controlled level of LDL-C in our prospective cohort study of 3,008 Chinese stroke patients and found that individuals with RCIR exhibit significantly higher risks of all-cause mortality, stroke-specific mortality, and unfavorable functional outcome compared to those with lower RC and hs-CRP levels. Notably, among patients with controlled RC (<28.62 mg/dL), high RIR was still associated with an increased risk of poor clinical outcomes. Recently, using data from the China Health and Retirement Longitudinal Study, Chen et al developed a novel composite biomarker RCII, which comprehensively reflected elevated RC and hs-CRP, and revealed that increased levels of RCII, whether at baseline or cumulatively, are significantly associated with an increased risk of stroke.18 In addition, a recent study from the National Health and Nutrition Examination Survey and China Health and Retirement Longitudinal Study reported significant relationships between RCII and all-cause, cardiovascular, and cancer mortality in the middle-aged and elderly populations.19 Our study further extended the clinical predictive significance of RCII to patients with ischemic stroke. Baseline RCII levels showed significant associations with risks of all-cause mortality, stroke-specific mortality, and unfavorable functional outcome. Furthermore, RCII optimizes the identification of high-risk stroke patients through enhanced predictive efficacy, as evidenced by C-statistics, NRI and IDI, providing a more precise risk stratification basis for clinical prognosis evaluation. RC and hs-CRP may interact to exacerbate atherosclerotic progression through interlinked inflammatory and lipid dysregulation pathways. RC accumulation in the arterial wall has been associated with local inflammation, impaired lipoprotein clearance, and macrophage activation, thereby promoting atherogenesis and plaque instability.27,32 hs-CRP, beyond reflecting systemic inflammation, may further amplify these processes by enhancing monocyte recruitment and cytokine release, promoting foam cell formation and fibrous cap degradation.33, 34, 35 Furthermore, chronic inflammation, driven in part by RC-induced inflammasome activation, may impair hepatic clearance of RC, establishing a vicious cycle of RC retention and inflammatory amplification.6,27 These findings suggest that both elevated RC and hs-CRP levels may exert joint impacts on adverse clinical outcomes after ischemic stroke. This prospective study was from the CATIS randomized clinical trial, standardized protocols and rigid quality control procedures were used for data collection and outcome assessment. Our cohort analysis provided evidence that patients with concurrent RC elevation and high hs-CRP levels face the highest risk of adverse clinical outcomes. In the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) trial, patients with higher baseline hs-CRP levels experienced greater absolute risk reductions of cardiovascular events from PCSK9 inhibitor therapy, and the lowest event rates were observed among those with low hs-CRP and LDL-C levels. These findings support the clinical relevance of both inflammatory and RCR, and highlight the potential value of dual-target strategies.36 Clinical trials are warranted to test the effects of controlling RC and hs-CRP in patients with ischemic stroke. Study limitations Several limitations deserve to be mentioned. First, participants were drawn from a random sample of the CATIS, and those with admission BP ≥220/120 mm Hg, atrial fibrillation and severe heart failure were excluded, so potential selection bias cannot be ruled out, and the generalizability of our findings may be limited.37 Second, the present study consisted solely of Chinese ischemic stroke patients; therefore, findings should be generalized cautiously to other populations. Third, RC was estimated indirectly rather than directly measured, which may introduce some inaccuracy. However, the method is easily applied in clinical practice and showed strong correlation with direct measurements.38 Finally, this was an observational study; thus, the possibility of residual confounding could not be fully excluded, although we did adjust for lots of the important confounders. Conclusions Our study provided the first evidence that elevated baseline RC and hs-CRP were synergistically associated with increased risks of long-term all-cause mortality, stroke-specific mortality, and unfavorable functional outcome in acute ischemic stroke patients. RCII manifested dose-dependent associations with adverse clinical outcomes and superior predictive capacity over established models. Our findings highlight the potential importance of jointly considering lipid metabolism and inflammation for risk stratification of ischemic stroke. Funding support and author disclosures This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (No. 82220108001, 82574196, and 82273706), the 10.13039/501100018556Suzhou Science and Technology Project (No. YW2024067), Discipline Construction Program of the 10.13039/501100014358Second Affiliated Hospital of Soochow University (XKTJ-XK202411-1), Interdisciplinary Basic Frontier Innovation Program of Suzhou Medical College of Soochow University (No. YXY2302013), and the Project of MOE Key Laboratory of Geriatric Diseases and Immunology (No. JYN202406), and a Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions, China. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.